Harrison S - Search Results

1

NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.

Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. Rasmussen DGK, et al. Among authors: harrison s. J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14. J Hepatol. 2023. PMID: 36526000 Free article. Review.

2

Corrigendum to "Pharmacotherapy for NASH: Current and emerging" [J Hepatol 68 (2017) 362-375].

Konerman MA, Jones JC, Harrison SA. Konerman MA, et al. J Hepatol. 2018 Jun;68(6):1337. doi: 10.1016/j.jhep.2018.03.002. Epub 2018 Mar 19. J Hepatol. 2018. PMID: 29567301 No abstract available.

3

Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.

Sanyal AJ, Foucquier J, Younossi ZM, Harrison SA, Newsome PN, Chan WK, Yilmaz Y, De Ledinghen V, Costentin C, Zheng MH, Wai-Sun Wong V, Elkhashab M, Huss RS, Myers RP, Roux M, Labourdette A, Destro M, Fournier-Poizat C, Miette V, Sandrin L, Boursier J. Sanyal AJ, et al. Among authors: harrison sa. J Hepatol. 2023 Feb;78(2):247-259. doi: 10.1016/j.jhep.2022.10.034. Epub 2022 Nov 12. J Hepatol. 2023. PMID: 36375686 Free PMC article.

4

Evaluation of PXL065 - deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1).

Harrison SA, Thang C, Bolze S, Dewitt S, Hallakou-Bozec S, Dubourg J, Bedossa P, Cusi K, Ratziu V, Grouin JM, Moller DE, Fouqueray P. Harrison SA, et al. J Hepatol. 2023 May;78(5):914-925. doi: 10.1016/j.jhep.2023.02.004. Epub 2023 Feb 18. J Hepatol. 2023. PMID: 36804402 Clinical Trial.

5

NASH cirrhosis trials and major adverse liver outcomes: Big data needed.

Noureddin M, Harrison SA. Noureddin M, et al. J Hepatol. 2023 Jan;78(1):5-7. doi: 10.1016/j.jhep.2022.10.022. Epub 2022 Oct 31. J Hepatol. 2023. PMID: 36328331 No abstract available.

6

MEFIB vs. MAST and FAST: Not a competition but useful tools.

Noureddin M, Harrison SA, Alkhouri N. Noureddin M, et al. J Hepatol. 2024 Jan;80(1):e35-e36. doi: 10.1016/j.jhep.2022.10.020. Epub 2022 Nov 10. J Hepatol. 2024. PMID: 36370950 No abstract available.

7

Hyperinsulinemia, an overlooked clue and potential way forward in metabolic dysfunction-associated steatotic liver disease.

Harrison SA, Dubourg J, Knott M, Colca J. Harrison SA, et al. Hepatology. 2023 Dec 5. doi: 10.1097/HEP.0000000000000710. Online ahead of print. Hepatology. 2023. PMID: 38051957

8

Management of Lysosomal Acid Lipase Deficiency for the Gastroenterologist and Hepatologist.

Harrison SA. Harrison SA. Gastroenterol Hepatol (N Y). 2016 May;12(5):331-3. Gastroenterol Hepatol (N Y). 2016. PMID: 27499717 Free PMC article. No abstract available.

9

HCV therapy in 2006: down with ALT levels, in with awareness of co-existent metabolic syndrome.

Harrison SA. Harrison SA. J Hepatol. 2006 Apr;44(4):624-6. doi: 10.1016/j.jhep.2006.02.001. Epub 2006 Feb 17. J Hepatol. 2006. PMID: 16503073 No abstract available.

10

Management of anemia in patients receiving protease inhibitors.

Harrison SA. Harrison SA. Gastroenterol Hepatol (N Y). 2012 Apr;8(4):254-6. Gastroenterol Hepatol (N Y). 2012. PMID: 22723756 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,381 results

Search Page